GAVRETO: payments to doctors
Payments that named GAVRETO as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $957K
- Providers
- 4,388
- Transactions
- 9,646
- Average per transaction
- $99
The per-transaction average — $99 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 4,388 providers the average total is $218, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Blueprint Medicines Corporation | $391,458 | 40.9% |
| Rigel Pharmaceuticals, Inc. | $382,495 | 40.0% |
| Genentech USA, Inc. | $167,643 | 17.5% |
| F. Hoffmann-la Roche AG | $7,485 | 0.8% |
| Hoffmann-la Roche Limited | $4,594 | 0.5% |
| Genentech, Inc. | $3,536 | 0.4% |